Charles River Laboratories Return on Tangible Equity 2010-2024 | CRL

Current and historical return on tangible equity values for Charles River Laboratories (CRL) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Charles River Laboratories Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2024-09-30 $0.42B $-0.12B -192.71%
2024-06-30 $0.44B $-0.15B -144.35%
2024-03-31 $0.44B $-0.25B -107.12%
2023-12-31 $0.47B $-0.36B -88.10%
2023-09-30 $0.47B $-0.46B -72.39%
2023-06-30 $0.48B $-0.59B -81.86%
2023-03-31 $0.50B $-0.75B -96.82%
2022-12-31 $0.49B $-0.82B -133.70%
2022-09-30 $0.44B $-0.20B -93.71%
2022-06-30 $0.44B $-0.27B -86.35%
2022-03-31 $0.42B $-0.15B -80.88%
2021-12-31 $0.39B $-1.23B -90.88%
2021-09-30 $0.40B $-0.39B -649.18%
2021-06-30 $0.40B $-0.31B 788.06%
2021-03-31 $0.38B $0.21B 328.23%
2020-12-31 $0.36B $0.24B 1693.02%
2020-09-30 $0.30B $0.05B -885.29%
2020-06-30 $0.27B $-0.05B -425.10%
2020-03-31 $0.25B $-0.16B -274.79%
2019-12-31 $0.25B $0.02B -854.24%
2019-09-30 $0.23B $-0.07B -667.63%
2019-06-30 $0.22B $-0.16B -572.55%
2019-03-31 $0.23B $0.09B -576.10%
2018-12-31 $0.23B $0.00B -22700.00%
2018-09-30 $0.14B $-0.08B 320.47%
2018-06-30 $0.13B $-0.17B 127.72%
2018-03-31 $0.13B $0.24B 74.89%
2017-12-31 $0.12B $0.18B 98.20%
2017-09-30 $0.20B $0.15B 261.39%
2017-06-30 $0.18B $0.12B 404.40%
2017-03-31 $0.17B $0.05B 1081.97%
2016-12-31 $0.16B $-0.02B 209.46%
2016-09-30 $0.14B $0.03B 103.27%
2016-06-30 $0.14B $-0.00B 106.21%
2016-03-31 $0.16B $0.29B 82.89%
2015-12-31 $0.15B $0.23B 93.02%
2015-09-30 $0.15B $0.01B 77.23%
2015-06-30 $0.14B $0.22B 58.64%
2015-03-31 $0.13B $0.19B 53.85%
2014-12-31 $0.13B $0.34B 44.21%
2014-09-30 $0.12B $0.22B 41.70%
2014-06-30 $0.12B $0.20B 37.20%
2014-03-31 $0.11B $0.39B 31.28%
2013-12-31 $0.10B $0.33B 31.35%
2013-09-30 $0.10B $0.34B 31.51%
2013-06-30 $0.09B $0.33B 29.64%
2013-03-31 $0.10B $0.31B 31.84%
2012-12-31 $0.10B $0.31B 33.05%
2012-09-30 $0.11B $0.30B 38.60%
2012-06-30 $0.10B $0.28B 39.96%
2012-03-31 $0.10B $0.27B 41.11%
2011-12-31 $0.11B $0.24B 44.04%
2011-09-30 $-0.26B $0.24B -93.32%
2011-06-30 $-0.31B $0.28B -95.63%
2011-03-31 $-0.32B $0.24B -73.89%
2010-12-31 $-0.34B $0.37B -60.41%
2010-09-30 $0.02B $0.39B 3.72%
2010-06-30 $0.09B $0.75B 12.02%
2010-03-31 $0.11B $0.73B 15.34%
2009-12-31 $0.11B $0.71B 17.06%
Sector Industry Market Cap Revenue
Medical Medical Services $8.361B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $89.358B 11.09
Cencora (COR) United States $46.783B 17.59
DiDi Global (DIDIY) China $22.844B 0.00
Natera (NTRA) United States $20.907B 0.00
ICON (ICLR) Ireland $16.343B 14.56
Avantor (AVTR) United States $15.048B 22.56
Revvity (RVTY) United States $14.408B 25.03
BioMerieux (BMXMF) France $13.788B 0.00
Viatris (VTRS) United States $13.488B 4.15
Solventum (SOLV) United States $12.699B 0.00
CochLear (CHEOY) Australia $12.341B 0.00
Medpace Holdings (MEDP) United States $10.485B 29.54
Doximity (DOCS) United States $10.029B 59.03
EUROFINS SCIENT (ERFSF) Luxembourg $9.551B 0.00
HealthEquity (HQY) United States $8.876B 44.53
Sonic Healthcare (SKHHY) Australia $8.244B 0.00
Amplifon S.p.A (AMFPF) Italy $6.136B 31.28
Bausch + Lomb (BLCO) Canada $6.118B 28.46
Organon (OGN) United States $4.054B 4.09
Sotera Health (SHC) United States $3.676B 19.67
BrightSpring Health Services (BTSG) United States $3.230B 68.70
Alignment Healthcare (ALHC) United States $2.795B 0.00
Concentras Parent (CON) United States $2.691B 0.00
Surgery Partners (SGRY) United States $2.566B 29.26
Premier (PINC) United States $2.156B 11.22
PACS (PACS) United States $2.106B 0.00
Ardent Health Partners (ARDT) United States $2.013B 0.00
GeneDx Holdings (WGS) United States $1.909B 0.00
Progyny (PGNY) United States $1.788B 36.21
GoodRx Holdings (GDRX) United States $1.742B 45.70
Ryman Healthcare (RYHTY) New Zealand $1.658B 0.00
Teladoc Health (TDOC) United States $1.565B 0.00
Agilon Health (AGL) United States $1.273B 0.00
Pediatrix Medical (MD) United States $1.189B 11.63
CareDx (CDNA) United States $1.150B 0.00
Embecta (EMBC) United States $1.086B 7.59
AMN Healthcare Services Inc (AMN) United States $0.986B 6.67
Establishment Labs Holdings (ESTA) $0.968B 0.00
Auna S.A (AUNA) Luxembourg $0.624B 0.00
SBC Medicals (SBC) United States $0.518B 0.00
InnovAge Holding (INNV) United States $0.484B 0.00
Sonida Senior Living (SNDA) United States $0.429B 0.00
QDM (QDMI) Hong Kong, SAR China $0.426B 11.15
DocGo (DCGO) United States $0.426B 16.04
Enhabit (EHAB) United States $0.402B 34.74
MultiPlan (MPLN) United States $0.260B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.239B 0.00
Sera Prognostics (SERA) United States $0.217B 0.00
Beauty Health (SKIN) United States $0.216B 0.00
LifeMD (LFMD) United States $0.212B 0.00
Nutex Health (NUTX) United States $0.206B 0.00
Performant Healthcare (PHLT) United States $0.181B 0.00
Biodesix (BDSX) United States $0.167B 0.00
So-Young (SY) China $0.110B 18.60
ModivCare (MODV) United States $0.093B 5.03
Ascend Wellness Holdings (AAWH) United States $0.085B 0.00
IceCure Medical (ICCM) Israel $0.068B 0.00
NeueHealth (NEUE) United States $0.062B 1.63
Singular Genomics Systems (OMIC) United States $0.050B 0.00
Oncology Institute (TOI) United States $0.042B 0.00
OncoCyte (OCX) United States $0.035B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.032B 0.00
Co-Diagnostics (CODX) United States $0.025B 0.00
Pheton Holdings (PTHL) China $0.025B 0.00
KindlyMD (KDLY) United States $0.009B 0.00
SeaStar Medical Holding (ICU) United States $0.008B 0.00
BioNexus Gene Lab (BGLC) $0.007B 0.00
XWELL (XWEL) United States $0.007B 0.00
Intelligent Bio Solutions (INBS) United States $0.006B 0.00
NewGenIvf Group (NIVF) Thailand $0.004B 0.00
ISpecimen (ISPC) United States $0.002B 0.00
Aclarion (ACON) United States $0.001B 0.00
Cano Health (CANOQ) United States $0.000B 0.00